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SUMMARY Background
Innate immunity cont ributes to the pathogenesis of autoimmune d iseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediat or interleukin-1 have been done. We aimed t o assess whether cana kinu mab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor ant agonist, improved f'-cell function in recent-onset type 1 diabetes.
Methods
We did two randomised, p lacebo-controlled tria ls in t wo g roups of patients with recent-onset type 1 diabetes and mixed-meal-tolerance-test-stimulated C peptide of at least 0.2 nM. Patients in t he cana kinumab trial were aged 6-45 years and those in the anakinra t rial were aged 18-35 years. Patients in the canakinumab trial were enrolled at 12 sites in the USA and Canada and those in the anakinra trial were enrolled at 14 sites across Europe. Participants were randomly assigned by computer-generated blocked randomisation to subcutaneous injection of either 2 mg/kg (maximum 300 mg) canakinumab or placebo monthly for 12 months or 100 mg anakinra or placebo daily for 9 months. Participants and carers were masked to treatment assignment. The primary endpoint was baseline-adjusted 2-h area under curve C-peptide response to the mixed meal tolerance test at 12 months (canakinumab trial) and 9 months (anakinra trial).
Analyses were by intention to treat. These studies are registered with ClinicaiTrials.gov, numbers NCT00947 427 and NCT00711503, and EudraCT number 2007-007146-34.
Findings
Patients were enrolled in the canakinumab trial between Nov 12, 2010, and April 11 , 2011 , and in the anakinra trial between Jan 26, 2009, and May 25, 2011. 69 patients were randomly assigned to canakinumab (n=47) or placebo (n=22) monthly for 12 months and 69 were randomly assigned to anakinra (n=35) or placebo (n=34) daily for 9 months. No interim analyses were done. 45 canakinumab-treated and 2 1 p lacebotreated p atients in the canakinumab trial and 25 anakinra-treated and 26 placebo-treated patients in the anakinra trial were included in the primary analyses. The difference in C peptide area under cu rve between the canakinumab and p lacebo groups at12 months was 0.01 nmoi/L (95% Cl -0.11 to 0.14; p=0.86), and between the anakinra and the placebo groups at 9 months was 0.02 nmoi/L (-0.09 t o 0.15; p=0.71 ). The number and severity of adverse events did not differ between groups in the canakinumab trial.
In the anakinra trial, patients in the anakinra group had signif icantly higher grades of adverse events than the placebo group (p=0.018), which was mainly because of a higher number of injection site reactions in the anakinra group.
Interpretation
Canakinumab and anakinra were safe but were not effective as single immunomodulatory drugs in recent-onset type 1 diabetes. lnterleukin-1 blockade might be more effective in combination with treatm ents that ta rget adaptive immunity in organ-specific autoimmune disorders.
INTRODUCTION
Type 1 diabetes mellitus is characterised by progressive autoimmune destruction of pancreatic~ cell s, resu lting in lifelong dependence on exogenous insulin administration and risk of acute and late complications. At initial diagnosis, substantial ~-cell function remains (1 ). Persistent endogenous insulin secret ion, def ined as stimulated C-peptide concentration greater than 0.2 nmoi/L during a mixed meal tolerance test (MMTT), is associated with reduced occurrence of severe hypoglycaemia and microvascular complicat ions (2, 3) . Thus, interventions that stop or delay decline of ~-cell function are desirable.
Clin ical t rials to preserve ~-cell function in newonset type 1 diabetes have focused on the adaptive immune system. Treatment with anti-CD3 (4-7) or abatacept (8) , wh ich target T lymphocytes, or anti-CD20 (9) which targets B lymphocytes, temporarily arrested the autoim mune pro cess, st abilising ~-cell function for about 6-12 months.
However, the disease recurred in all of these cases, consistent with transient suppression of the adaptive immune system rather than durable immunomodulation .
Recent research has focused on the role of the innate immune system in type 1 diabetes. Findings from a pilot clin ica l trial suggested that inhibition of tumour necrosis factor-a might have a beneficial effect in type 1 diabetes (1 0) However, particular attention has focused on the role of the proinflammatory cytokine interleukin-1 ~.
which is secreted by several ce ll t ypes in response to tissue insult. By binding to pancreatic ~-cell int erleukin-1 type 1 receptors, interleukin-1 signals ~-ce l l secretory dys function and apoptosis via the nuclear factor KB and mit ogen-activated protein kinase pathways, leading to endoplasmic reticu lum and mitochondrial stress (11 ) .
Hyperglycaemia also induces production and re lease of interleukin-1 ~ by pancreatic ~ cells (12) ; int erleukin-113 seems to act locally to inh ibit insu lin biosynthesis and release (13, 14) and induce 13-cell apoptosis via activation of the death receptor Fas (12, 15) . Because of its direct 13-cell proapoptotic action and mediatory effects on pancreatic 13-cell glucotoxicity, interleukin-1 ~has been implicated in the pathogenesis of both type 1 and type 2 diabetes.
In addition to its effects in the innate immune syst em, interleukin-1 13 might be important in the pathogenesis of type 1 diabetes via its role as a potent amplifier of the adaptive immune response. lnterleukin-113 enhances expansion and survival of naive and memory T lymphocytes, promotes differentiat ion ofT lymphocytes towards pathological phenotypes including T-helper-1 (Th 1) and Th17, and enables effector T lymphocytes to proliferate despite the modulating presence of regulatory T lymphocyt es (16) . lnterleukin-113 might also have an important role in monocyte trafficking (17) .
Th us, there is a strong preclin ical rationale to implicate interleukin-1 as an immune mediator of pancreatic 13-cell destruction leading to type 1 d iabetes (11 ) . 
METHODS
Participants
Bot h studies were investigator-initiated, para llel-group, randomised, placebo- The protocols and consent documents were approved by independent ethics committees o r institutional review boards. A ll participants or parents provided written informed consent before enrolment, and participants younger than 18 years provided assent. Independent data and safety reviews were undertaken regu larly.
Randomisation and masking
Patients were individually randomised by the data monitoring unit common for both trials by a centralised computer-generated random allocation sequence with locked computer file conceal ment. The TriaiNet canakinumab st udy used 2:1 random isat ion in permut ed blocks of six, and the AIDA trial used 1:1 randomisation in blocks of four within recruiting centres. All participants and investigators were masked to treatment assignment.
Procedures
Screening, enrolment, and study visits took place at 12 TriaiNet sites in the USA and Adverse events were coded using t he Common Terminology Criteria for Adverse Events (CTCAE). version 3.0, with relation to study drug assessed by the investigators .
Statistical analysis
For the canakinumab trial, a sample size of 66 patients was needed to provide 85% power to detect a 54% increase in the transformed mean of C peptide in the canakinumab treatment group relative to the placebo group, with a one-sided test at a =O.OS and 10% missing values. Screening of new patients was closed before this target sample size was reached but patients who had already begun screening were allowed to proceed.
For the anakinra trial, a sample size of 80 patients in each group (160 patients in total) was needed to provide 80% power to det ect a 30% difference in t he C-peptide AUC between treatment groups, with a two-sided test at a=O.OS and 10% missing values.
All analyses were based on the prespecified intention-to-treat cohorts w ith known measurements (complete case analysis); missing values we re assumed to be missing at random . The p values are two-sided unless otherwise specified. The significance levels associated with the treatment effect were from t he Wald test (f rom the fitted model).
Treatment comp arisons of adverse event grades w ere analysed wit h the Wilcoxon rank sum test and the occurrence of each adverse effect type was analysed with the Fish er's exact test (one-sided tests). Spot fire S+ (version 8.1) was used for all analyses.
We used an ANCOVA model adjusted for age, sex, baseline value of the dependent variable, and t reatment assignment to analyse the mean AUC of C peptide, percentage of HbA 1 c, and total daily insulin dose. The predicted means and associat ed 95% Cls for each treatment group were ca lculated at the means of the other covariates.
A normalising transf ormation of log (Xc-peptide + 1) was pre specified for th e mean AUC of C peptide, and normal plots of the residua ls suggested that t his was adequate (data not shown). The unadjusted geometric-like mean was calculated using the same transformation and was then averaged and the inve rse transformation was applied. The mean AUC of C peptide is equal to the AUC divided by the 2-h interva l. there was no statistical evidence to suggest t hat value was anything other th an zero.
The 95% Cls fo r the difference in the population means of C peptide and the percent decrease of C peptide from baseline were determined using a bootstrap t echnique.
The TriaiNet canakinumab and AIDA tria ls are registered with Cli nicaiTria ls.
gov, numbers NCT00947427 and 00711503, respectively, and the AIDA trial is also registered as EudraCT number 2007-007146-34.
RESULTS
Canakinumab trial
Between Nov 12, 2010, and April 11, 2011 , 105 participants were assessed for eligibility and 69 were randomly assigned; 47 to canakinumab and 22 to placebo (figure 1; appendix (3.1-51.6) reduction in the population means of C peptide in the canakinumab and placebo groups, respectively. When the populat ion means were assumed to be linear over time in a mixed model, the decay rates (ie, slopes) were not different between the groups (appendix). Time to stimulated peak C peptide less than 0.2 nmoi / L also did not differ between the two groups (appendix). Percentages of HbA 1 c increased gradually over time and we re simi lar between canakinumab-treated and placebotreated participants at 1 year (p=O. 7 6; appendix). Similarly, there was no difference in insu li n dose at 1 yea r between groups (p= 0.53; appendix).
In a predefined subgroup analysis, a homogeneity test of treatment effect on age, mm3): one instance each in two canakinumab-treated patients and two instances in a patient on placebo. In al l but one of t hese cases (the placebo-treated patient), several doses of study drug were not associated with subsequent neutropenia.
49
The groups were we ll balanced for cl in ical and d em ographic characteristics with the exception of interleukin-6 and interleukin-1 recept or antagonist concentrations (table 4) . For interleukin-6 concentration, the rep orted difference was attributable t o one extreme value that dist orted the mean and standard deviation for t he placeb o group. For interleukin-1 receptor antagonist concentration, t here were two extreme values that distorted the mean and st andard deviation for the anakinra group.
Population means for t he 2 h AUC of stimulat ed C peptide adjusted for age, sex, and baseline C-pep tide val ue were similar between the groups at 9 months (a nakin ra free state with maintenance of a HbA 1 c percent age less than 7.5%. Table 4 : Baseline demographics and laboratory characterist ics o f participants in the anakin ra trial.
Anakinra (n=35) Placebo (n=34)
Age ( Data are number (%) or mean (SD) unless otherwise specifi ed. *Excludes two participants in the anakinra group and one in the placebo group who did not report ethnic origin. tData missing for two patients in the anakinra group and two in the placebo group. :!:Data missing for three patients in the anakinra g roup and two in t he placebo group. §Data missing for three pat ients in the anakinra group. ~Data missing for one pat ient in the anakin ra g roup and t hree in the p lacebo group. IIData missing for one patient in t he anakinra group. **Data missing for one patient in the placebo group. A predefined subgroup analysis of treatment effect was d one within the fol lowing variables: age, sex, ethnic origin, baseline C peptide, baseline body-mass index, insulin use, HbA 1 c, HLA type, and sympt om duration. Only the interaction between treatment and the three categorised levels of C p eptide was statistically significant (p=0.006; appendix).
The anakinra group rep orted significant ly higher g rades of ad verse events than the placebo group (p =0.0 18, onesided Wilcoxon rank sum test). primarily as a result of the higher frequency of grade 2 events in t he anakinra group (table 5) . Analysis of adverse events by category revealed that dermatological and ski n event s was the only category that was significantly d ifferent between treatment groups (p=0.017, one-sided Fisher's exact test; table 6). This difference was attributable t o 17 and four participants with injection site reactions from the anakinra and pl acebo groups, respectively (p=0.0009).
DISCUSSION
Our results show th at inhibition of interleukin-1 ~with canakinumab or anakinra did not slow ~-cell decline in recent-onset t ype 1 diabetes. At the end of the two t ria ls, stimulated C-peptide concentrations and percentages of HbA 1 c did not differ between interventiontreated and placebo-treated pat ients. Although bot h tria ls stud ied individuals with recentonset type 1 diabetes, their entry criteria-particularly rega rding age-and their trial Data are number of participants(%). Worst g rade was statistically signifi cantly different between t reatment groups by a one-sided (alternative of higher frequency in anakinra group) Wilcoxon rank sum test (p=0·018). Some percentages do not t ota l 100 because o f rounding. Each adverse event category by treatment group was tested using a one-sided Fisher's exact test. Only the difference between groups in the adverse event category dermatological or skin reached statistica l signifi cance (p=0·017). Of t he 28 participants who had dermatological or ski n reactions, 21 had injection-site reactions, 17 o f whom were from the anakinra g roup (p=0·0009).
design were d ifferent. Enrolment proceeded rapidly in the canakinumab study, probably because of the enthusiasm of younger patients and their parents for participation in clinical trials. The anakinra st udy had slow enrolment and was stopped owing to slow recruitment. The protocol was more demanding for patients in the anakinra study because daily injections were needed by the participants, whereas in the canakinumab trial there were monthly injections of drug at the clinical sites. Time on Study (months) Time on Study (months) .. 
